BARD1 isoforms in lung and colorectal cancer and use thereof

Patent metadata

Field	Value
Publication number	US-11022612-B2
Application number	US-201715417363-A
Country	US
Kind code	B2
Filing date	Jan 27, 2017
Priority date	Aug 17, 2010
Publication date	Jun 1, 2021
Grant date	Jun 1, 2021

Abstract

The present invention relates to new BARD1 isoforms specific to lung cancer and colorectal cancer, a method for detecting thereof and a method for treating and/or preventing lung cancer and colorectal cancer.

First claim

The invention claimed is:

1. A method for detecting the presence of a BARD1 isoform specific to lung cancer and colorectal cancer, the method comprising the steps of:
obtaining a biological sample from a subject;
detecting in said biological sample autoantibodies specific for detecting a BARD1 isoform κ consisting of sequence SEQ ID NO:2 or a sequence having at least 99% homology to SEQ ID NO:2 by performing an immunoassay, wherein said step of performing an immunoassay comprises the steps:
a) providing at least four different antigen peptides selected from the group consisting of SEQ ID NOs: 16, 17, 18, 23, 68, 69, 74, 75 and antigen peptides corresponding to a region wholly within the deletion within exon 4 of BARD1 isoform π and wherein said antigen peptides are immobilized on a solid support;
b) bringing said biological sample into contact with said antigen peptides, and
c) detecting complexes formed between autoimmune antibodies and said antigen peptides, thereby detecting the presence of a BARD1 isoform specific to lung cancer and colorectal cancer,
wherein the presence of said BARD1 isoform κ in a sample from said subject is an indication that said subject is afflicted with lung cancer and/or colorectal cancer, has an increased risk of lung cancer and/or colorectal cancer, a risk of recurrence after a treatment for lung cancer and/or colorectal cancer, and/or is an indication of reduced survival of a patient afflicted with lung cancer.

2. The method of claim 1 , wherein said biological sample is selected from the group consisting of a biopsy sample, a histology sample, lung liquids, frozen tissue sample, tumor tissue sample, feces sample, cerebrospinal fluid (CSF), circulating tumour cells (CTC) and blood sample.

3. The method of claim 2 , wherein said biological sample is a blood sample.

4. A method for detecting the presence of a BARD1 isoform specific to lung cancer and colorectal cancer, the method comprising the steps of:
obtaining a biological sample from a subject;
detecting in said biological sample autoantibodies specific for detecting a BARD1 isoform κ consisting of sequence SEQ ID NO:2 or a sequence having at least 99% homology to SEQ ID NO:2, and detecting in said biological sample autoantibodies specific for a BARD1 isoform π consisting of sequence SEQ ID NO:1 or a sequence having at least 99% homology to SEQ ID NO:1 by performing an immunoassay, wherein said step of performing an immunoassay comprises the steps:
a) providing at least four different antigen peptides selected from the group consisting of SEQ ID NOs: 16, 17, 18, 23, 68, 69, 74, 75 and antigen peptides corresponding to a region wholly within the deletion within exon 4 of BARD1 isoform π and wherein said antigen peptides are immobilizes on a solid support;
b) bringing said biological sample into contact with said antigen peptides, and
c) detecting complexes formed between autoimmune antibodies and said antigen peptides, thereby detecting the presence of a BARD1 isoform specific to lung cancer and colorectal cancer,
wherein the presence of said BARD1 isoform κ and/or BARD1 isoform π in a sample from said subject is an indication that said subject is afflicted with lung cancer and/or colorectal cancer, has an increased risk of lung cancer and/or colorectal cancer, a risk of recurrence after a treatment for lung cancer and/or colorectal cancer, and/or is an indication of reduced survival of a patient afflicted with lung cancer.

5. The method of claim 4 , wherein said biological sample is selected from the group consisting of a biopsy sample, a histology sample, lung liquids, frozen tissue sample, tumor tissue sample, feces sample, cerebrospinal fluid (CSF), circulating tumour cells (CTC) and blood sample.

6. The method of claim 5 , wherein said biological sample is a blood sample.

Assignees

• Univ Geneve
• Hopitaux Univ De Geneve
• Univ De Geneva

Inventors

• Irminger-Finger Irmgard
• Zhang yong-qiang

Classifications

• G01N33/57535

  of the large intestine, e.g. colon, rectum or anus · CPC title

• G01N33/5752 Primary

  of the lungs · CPC title

• G01N2333/4703

  Regulators; Modulating activity · CPC title

• C07K16/40

  against enzymes · CPC title

• C12N2320/30

  Special therapeutic applications · CPC title